Short-term ADT with RT improves survival over RT alone up to 10 years

(NRG Oncology) The long-term follow up of the NRG Oncology trial RTOG 9408, studying the addition of short-term androgen-deprivation therapy (ADT) to radiotherapy (RT) for men with early, localized prostate adenocarcinoma, indicated that RT combined with ADT is superior to RT alone for overall survival (OS) up to 10.4 years following treatment. However, when researchers assessed these results up to 18 years, the benefits of adding ADT to RT dissipated.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news